First Time Loading...

Atara Biotherapeutics Inc
NASDAQ:ATRA

Watchlist Manager
Atara Biotherapeutics Inc Logo
Atara Biotherapeutics Inc
NASDAQ:ATRA
Watchlist
Price: 0.677 USD -2.13%
Updated: Apr 19, 2024
Section:
 

Wall Street
Price Targets

ATRA Price Targets Summary
Atara Biotherapeutics Inc

Wall Street analysts forecast ATRA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ATRA is 4.284 USD with a low forecast of 0.505 USD and a high forecast of 13.65 USD.

ATRA Lowest Forecast
Wall Street Target
0.505 USD
25% Downside
ATRA Average Forecast
Wall Street Target
4.284 USD
533% Upside
ATRA Highest Forecast
Wall Street Target
13.65 USD
1 916% Upside
Lowest
Price Target
0.505 USD
25% Downside
Average
Price Target
4.284 USD
533% Upside
Highest
Price Target
13.65 USD
1 916% Upside
Atara Biotherapeutics Inc Competitors:
Price Targets
PRLD
Prelude Therapeutics Inc
72% Upside
TNGX
Tango Therapeutics Inc
143% Upside
TSVT
2Seventy Bio Inc
138% Upside
ABIO
ARCA Biopharma Inc
115% Upside
PRLD
Prelude Therapeutics Inc
72% Upside
TNGX
Tango Therapeutics Inc
143% Upside
TSVT
2Seventy Bio Inc
138% Upside
ABIO
ARCA Biopharma Inc
115% Upside
BYSI
Beyondspring Inc
30% Downside
S
688336
Sunshine Guojian Pharmaceutical Shanghai Co Ltd
57% Upside
PSTX
Poseida Therapeutics Inc
614% Upside
XOMA
XOMA Corp
195% Upside

Revenue
Forecast

Revenue Estimate
Atara Biotherapeutics Inc

The compound annual growth rate of Atara Biotherapeutics Inc's revenue for the next 3 years is 101%.

N/A
Past Growth
101%
Estimated Growth
Estimates Accuracy
-46%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Atara Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Atara Biotherapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-50%
Average Miss
What are analyst estimates?

See Also

Summary
ATRA intrinsic value, competitors valuation, and company profile.
DCF Valuation
ATRA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ATRA stock valuation using valuation multiples.
Wall Street Estimates
ATRA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ATRA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ATRA's stock price target?
Price Target
4.284 USD

According to Wall Street analysts, the average 1-year price target for ATRA is 4.284 USD with a low forecast of 0.505 USD and a high forecast of 13.65 USD.

What is Atara Biotherapeutics Inc's Revenue forecast?
Projected CAGR
101%

The compound annual growth rate of Atara Biotherapeutics Inc's revenue for the next 3 years is 101%.

ALPHA SPREAD
Join more than 129,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.